nicotine has been researched along with paroxetine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Fortmann, SP; Hayward, C; Killen, JD; Rothman, M; Schatzberg, AF; Strausberg, L; Sussman, L; Varady, A | 1 |
| File, SE; Kenny, PJ; Neal, MJ | 1 |
| Kamei, K; Kato, H; Mimura, Y; Muneoka, K; Ogawa, T; Takigawa, M | 1 |
| Ali, SF; Seidler, FJ; Slikker, W; Slotkin, TA; Xu, Z | 1 |
| Fortmann, SP; Hayward, C; Killen, JD; Schatzberg, A; Varady, A | 1 |
| Camarasa, J; Escubedo, E; Garcia-Ratés, S; Pubill, D | 1 |
1 review(s) available for nicotine and paroxetine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
2 trial(s) available for nicotine and paroxetine
| Article | Year |
|---|---|
Nicotine patch and paroxetine for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Paroxetine; Patient Compliance; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome | 2000 |
Onset of major depression during treatment for nicotine dependence.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Paroxetine; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2003 |
13 other study(ies) available for nicotine and paroxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release.
Topics: Animals; Calcium; Calcium Channel Blockers; Carrier Proteins; Dose-Response Relationship, Drug; Hippocampus; In Vitro Techniques; Male; Mecamylamine; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Paroxetine; Rats; Rats, Inbred Strains; Receptor, Muscarinic M1; Receptors, GABA-A; Receptors, Glutamate; Receptors, Muscarinic; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tetrodotoxin | 2000 |
Nicotine exposure during pregnancy is a factor which influences serotonin transporter density in the rat brain.
Topics: Animals; Brain Chemistry; Carrier Proteins; Female; Infusion Pumps; Injections, Subcutaneous; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2001 |
Fetal and adolescent nicotine administration: effects on CNS serotonergic systems.
Topics: Aging; Animals; Binding Sites; Brain; Carrier Proteins; Embryo, Mammalian; Female; Hydroxyindoleacetic Acid; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Nicotine; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sex Characteristics; Synaptic Transmission; Tobacco Use Disorder | 2001 |
3,4-Methylenedioxy-methamphetamine induces in vivo regional up-regulation of central nicotinic receptors in rats and potentiates the regulatory effects of nicotine on these receptors.
Topics: Aconitine; Animals; Blotting, Western; Brain; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Drug Synergism; Immunoprecipitation; Injections, Subcutaneous; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nicotine; Nicotinic Agonists; Paroxetine; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Serotonin Plasma Membrane Transport Proteins; Time Factors; Up-Regulation | 2013 |